Compare JD.Com Inc (JD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs ResMed Inc. — how do they compare? JD.Com Inc trades at $26.95 (market cap $36.62B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: JD.Com Inc and ResMed Inc. are close in size by market cap, and JD.Com Inc pays the higher dividend (3.72%). Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and ResMed Inc. for 51 Days on average.
| JD | RMD | |
|---|---|---|
Market Cap | $36.62B | $31.89B |
Volume | 6,571,477 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $277.88 |
52-Week Low | $25.19 | $182.82 |
Typical Hold Time | 85 Days | 51 Days |
Enterprise Value | $19.26B | $31.24B |
Dividend Yield | 3.72% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com stock trades at $27.03, up 2.0% today, with a bullish technical signal and strong analyst consensus. The company reported revenue of $1.31 trillion in 2025, though net income declined to $19.63 billion. Recent news highlights potential EU approval for its $2.5 billion Ceconomy acquisition, a key strategic move.
The outlook is positive given deep valuation discounts (P/E 17.9, P/S 0.2) and robust cash flow, but risks include revenue pressure and regulatory scrutiny. Analyst price targets average $35.86, implying significant upside from current levels if execution improves.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
